Patents by Inventor Donald L. Durden

Donald L. Durden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200181164
    Abstract: The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral, bacterial or fungal infection, atherosclerosis, Type 1 or 2 diabetes, obesity, inflammatory disease, and/or SYK-associated disorder including by modulating biological processes through the inhibition of SYK alone, or in combination with inhibition of one or more of PI3 kinase including PI3K-gamma isoform, BET bromodomain proteins, CDK 4/6, and checkpoint proteins, comprising the administration of a compound(s) of Formula I-V (or pharmaceutically acceptable salts thereof) as defined herein.
    Type: Application
    Filed: June 5, 2018
    Publication date: June 11, 2020
    Applicant: SignalRx Pharmaceuticals, Inc.
    Inventors: Guillermo A. MORALES, Joseph R. GARLICH, Donald L. DURDEN
  • Publication number: 20190367530
    Abstract: The invention relates to compounds and methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis. Type 1 or 2 diabetes, obesity, inflammatory disease, or Myc-depenent disorder including by modulating biological processes by the inhibition of cell cycle checkpoint targets CDKs, and/or PI3 kinase, and/or bromodomain protein binding to substrates, comprising the administration of a compound(s) of Formula 1-VI (or pharmaceutically acceptable salts thereof) as defined herein.
    Type: Application
    Filed: January 26, 2018
    Publication date: December 5, 2019
    Applicant: SignalRx Pharmaceuticals, Inc.
    Inventors: Guillermo A. Morales, Joseph R. Garlich, Donald L. Durden
  • Patent number: 10308662
    Abstract: The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis, Type 1 or 2 diabetes, obesity, inflammatory disease, or Myc-depenent disorder including by modulating biological processes by the inhibition of PI3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of Formula I-IX (or pharmaceutically acceptable salts thereof) as defined herein.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: June 4, 2019
    Assignee: Signal Rx Pharmaceuticals., Inc.
    Inventors: Donald L. Durden, Guillermo A. Morales, Joseph R. Garlich
  • Patent number: 10174032
    Abstract: The invention relates to compounds of Formulas I-VII (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating cellular signaling pathways and biological processes associated therewith including inhibition of kinase activity such as PI-3 kinase or inhibition of bromodomain proteins or both at the same time as well as to therapeutic methods for treating a disease associated with aberrant PI3K and/or bromodomain proteins.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: January 8, 2019
    Assignee: SignalRx Pharmaceuticals, Inc.
    Inventors: Guillermo A Morales, Joseph R. Garlich, Kevin T. Weber, Jessica M. Newblom, Donald L. Durden
  • Publication number: 20170334925
    Abstract: The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis, Type 1 or 2 diabetes, obesity, inflammatory disease, or Myc-depenent disorder including by modulating biological processes by the inhibition of PI3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of Formula I-IX (or pharmaceutically acceptable salts thereof) as defined herein.
    Type: Application
    Filed: August 9, 2017
    Publication date: November 23, 2017
    Applicant: SignalRx Pharmaceuticals, Inc.
    Inventors: Donald L. Durden, Guillermo A. Morales, Joseph R. Garlich
  • Publication number: 20170101418
    Abstract: The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infection, atheroscleosis, Type 1 or 2 diabetes, obesity, inflammatory disease, or Myc-depenent disorder including by modulating biological processes by the inhibition of PI3 kinase and/or bromodomain protein binding to substrates comprising the administration of a compound(s) of Formula I-IX (or pharmaceutically acceptable salts thereof) as defined herein.
    Type: Application
    Filed: October 19, 2016
    Publication date: April 13, 2017
    Applicant: SignalRx Pharmaceuticals, Inc.
    Inventors: Donald L. Durden, Guillermo A. Morales, Joseph R. Garlich
  • Patent number: 9505780
    Abstract: The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis, Type 1 or 2 diabetes, obesity, inflammatory disease, or Myc-depenent disorder including by modulating biological processes by the inhibition of PI3 kinase and/or bromodomain protein binding to substrates composing the administration of a compound(s) of Formula I-IX (or pharmaceutically acceptable salts thereof) as defined herein.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: November 29, 2016
    Assignee: SignalRx Pharmaceuticals, Inc.
    Inventors: Donald L. Durden, Guillermo A. Morales, Joseph R. Garlich
  • Patent number: 9353366
    Abstract: Disclosed herein are polypeptides which exhibit asparaginase activity and little to no glutaminase activity. The polypeptides have sequences which correspond to W. succinogenes asparaginase, but have an amino acid residue other than proline at amino acid position 121. The polypeptides exhibit higher kinetic rates of asparaginase activity to glutaminase activity as compared to W. succinogenes asparaginase and Elspar®, an E. coli asparaginase.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: May 31, 2016
    Assignee: Children's Hospital Los Angeles
    Inventor: Donald L. Durden
  • Publication number: 20150344494
    Abstract: The invention relates to methods of treating diseases including but not limited to, cancer non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis, Type 1 or 2 diabetes, obesity, inflammatory disease, or Myc-depenent disorder including by modulating biological processes by the inhibition of PI3 kinase and/or bromodomain protein binding to substrates composing the administration of a compound(s) of Formula I-IX (or pharmaceutically acceptable salts thereof) as defined herein.
    Type: Application
    Filed: May 4, 2015
    Publication date: December 3, 2015
    Applicant: SIGNALRX PHARMACEUTICALS, INC.
    Inventors: Donald L. Durden, Guillermo A. Morales, Joseph R. Garlich
  • Publication number: 20150315207
    Abstract: The invention relates to compounds of Formulas I-VII (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating cellular signaling pathways and biological processes associated therewith including inhibition of kinase activity such as PI-3 kinase or inhibition of bromodomain proteins or both at the same time as well as to therapeutic methods for treating a disease associated with aberrant PI3K and/or bromodomain proteins.
    Type: Application
    Filed: May 4, 2015
    Publication date: November 5, 2015
    Applicant: SignalRx Pharmaceuticals, Inc.
    Inventors: Guillermo A Morales, Joseph R. Garlich, Kevin T. Weber, Jessica M. Newblom, Donald L. Durden
  • Publication number: 20150307866
    Abstract: Disclosed herein are polypeptides which exhibit asparaginase activity and little to no glutaminase activity. The polypeptides have sequences which correspond to W. succinogenes asparaginase, but have an amino acid residue other than proline at amino acid position 121. The polypeptides exhibit higher kinetic rates of asparaginase activity to glutaminase activity as compared to W. succinogenes asparaginase and Elspar®, an E. coli asparaginase.
    Type: Application
    Filed: May 7, 2015
    Publication date: October 29, 2015
    Applicant: CHILDREN'S HOSPITAL LOS ANGELES
    Inventor: Donald L. Durden
  • Publication number: 20140248255
    Abstract: Disclosed herein are polypeptides which exhibit asparaginase activity and little to no glutaminase activity. The polypeptides have sequences which correspond to W. succinogenes asparaginase, but have an amino acid residue other than proline at amino acid position 121. The polypeptides exhibit higher kinetic rates of asparaginase activity to glutaminase activity as compared to W. succinogenes asparaginase and Elspar®, an E. coli asparaginase.
    Type: Application
    Filed: October 9, 2012
    Publication date: September 4, 2014
    Applicant: CHILDREN'S HOSPITAL LOS ANGELES
    Inventor: Donald L. Durden
  • Publication number: 20120253020
    Abstract: Methods are provided for the identification, biochemical characterization and therapeutic use of agents which impact PTEN, p53, PI-kinase and AKT mediated cellular signaling.
    Type: Application
    Filed: April 24, 2012
    Publication date: October 4, 2012
    Inventor: Donald L. Durden
  • Patent number: 8163691
    Abstract: Methods are provided for the identification, biochemical characterization and therapeutic use of agents which impact PTEN, p53, PI-kinase and AKT mediated cellular signaling.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: April 24, 2012
    Assignee: Indiana University Research & Research Corporation
    Inventor: Donald L. Durden
  • Publication number: 20100286141
    Abstract: Methods are provided for the identification, biochemical characterization and therapeutic use of agents which impact PTEN, p53, PI-kinase and AKT mediated cellular signaling.
    Type: Application
    Filed: June 29, 2010
    Publication date: November 11, 2010
    Inventor: Donald L. Durden
  • Patent number: 7745485
    Abstract: Methods are provided for the identification, biochemical characterization and therapeutic use of agents which impact PTEN, p53, PI-kinase and AKT mediated cellular signaling.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: June 29, 2010
    Assignee: Indiana University Research and Technology Corporation
    Inventor: Donald L. Durden
  • Patent number: 7662977
    Abstract: The invention provides novel prodrugs of inhibitors of PI-3 kinase. The novel compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: February 16, 2010
    Assignee: Semafore Pharmaceuticals, Inc.
    Inventors: Joseph R. Garlich, Donald L. Durden, Mary Patterson, Jingdong Su, Robert G. Suhr
  • Publication number: 20090162338
    Abstract: Methods are provided for the identification, biochemical characterization and therapeutic use of agents which impact PTEN, p53, PI-kinase and AKT mediated cellular signaling.
    Type: Application
    Filed: December 23, 2008
    Publication date: June 25, 2009
    Inventor: Donald L. Durden
  • Publication number: 20090011975
    Abstract: The invention provides a method of inhibiting cell death in a mammal. The method comprises administering to a mammal an effective amount of a composition comprising a cell protection factor covalently linked to a bone targeting agent via a linkage that is cleaved under physiological conditions, whereby the cell protection factor is released from the bone targeting agent in vivo to inhibit cell death. The invention further provides a compound comprising a cell protection factor covalently attached to a bone targeting agent via a linker that is cleaved under physiological conditions.
    Type: Application
    Filed: July 31, 2008
    Publication date: January 8, 2009
    Applicant: Semafore Pharmaceuticals Inc.
    Inventors: Joseph R. Garlich, Donald L. Durden, Tim C. Smith
  • Patent number: 7470721
    Abstract: Methods are provided for the identification, biochemical characterization and therapeutic use of agents which impact PTEN, p53, PI-kinase and AKT mediated cellular signaling.
    Type: Grant
    Filed: November 13, 2003
    Date of Patent: December 30, 2008
    Assignee: Indiana University Research and Technology Corporation
    Inventor: Donald L. Durden